Looking Towards the Future of Oncology Treatment
Looking Towards the Future of Oncology Treatment
At Daiichi Sankyo we aim to create essential medicine for longer, better lives. The core and catalyst behind our oncology development plan is our DXd ADC Technology. ADCs, or antibody drug conjugates, are therapies that combine 3 components—an antibody connected to a payload via a linker.
What makes Daiichi Sankyo’s DXd ADC Technology unique is our linker and payload. Explore the origins behind Daiichi Sankyo’s proprietary DXd ADC Technology and learn how this innovative approach provides targeted cancer therapy through our new video series: The Making of DXd ADC.
Looking Towards the Future of Oncology:
Ken Keller, Global Head of the Oncology Business, explores the organization’s goals with DXd ADC Technology and how Daiichi Sankyo seeks to go beyond making incremental differences, by striving to create new standards of care for people with cancer around the world.
Discover the Design Behind DXd Antibody Drug Conjugates (ADCs):
Mark Rutstein, Global Head of Oncology Clinical Development, discusses the linker-payload, the core of Daiichi Sankyo’s DXd ADC Technology. He discusses how the traits of DXd ADC Technology aim to help patients with unmet medical needs.
OurStorySuggestions
Suggestions
Not all breast cancers are the same. This is particularly true about metastatic breast cancer versus early-stage breast cancer in terms of how the disease spreads, its prognosis, treatment options, and even the patient journey.
View more
Daiichi Sankyo honors its Japanese heritage and connection to the cherry blossom trees in Washington, D.C. as a perennial sponsor of the National Cherry Blossom Festival. Learn about the special link and watch a video capturing the joy felt by Daiichi Sankyo employees participating in the festival parade.
View more
Translating facts into memorable stories is a powerful craft. Discover how Daiichi Sankyo communications leader Kim Wix inspires action via storytelling.
View more